Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Naoto KatakamiTomoya MitaHidenori YoshiiToshihiko ShiraiwaTetsuyuki YasudaYosuke OkadaKeiichi TorimotoYutaka UmayaharaHideaki KanetoTakeshi OsonoiTsunehiko YamamotoNobuichi KuribayashiKazuhisa MaedaHiroki YokoyamaKeisuke KosugiKentaro OhtoshiIsao HayashiSatoru SumitaniMamiko TsugawaKayoko RyomotoHideki TakiTadashi NakamuraSatoshi KawashimaYasunori SatoHirotaka WatadaIichiro Shimomuranull nullPublished in: Cardiovascular diabetology (2021)
Tofogliflozin significantly inhibited the increased baPWV in patients with T2DM without a history of apparent cardiovascular disease, suggesting that tofogliflozin suppressed the progression of arterial stiffness. Trial Registration UMIN000017607. Registered 18 May 2015. ( https://www.umin.ac.jp/icdr/index.html ).
Keyphrases
- phase iii
- open label
- phase ii
- clinical trial
- study protocol
- cardiovascular disease
- blood pressure
- double blind
- placebo controlled
- phase ii study
- randomized controlled trial
- type diabetes
- radiation therapy
- skeletal muscle
- metabolic syndrome
- squamous cell carcinoma
- computed tomography
- insulin resistance
- coronary artery disease
- diffusion weighted imaging